[A19-56] Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2019
Commission awarded on 11.07.2019 by the Federal Joint Committee (G-BA).
Women whose advanced BRCA1/2-mutated high-grade epithelial ovarian cancer has responded completely or partially to first-line platinum-based chemotherapy
Several hints of greater harm regarding side effects; no informative results regarding overall survival. Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.